ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Mersana Therapeutics Inc

Mersana Therapeutics Inc (MRSN)

2.08
0.05
(2.46%)
Closed July 14 4:00PM
2.09
0.01
(0.48%)
After Hours: 7:59PM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
2.08
Bid
1.50
Ask
2.21
Volume
1,025,612
2.02 Day's Range 2.16
0.8014 52 Week Range 6.2801
Market Cap
Previous Close
2.03
Open
2.08
Last Trade
15
@
2.03
Last Trade Time
Financial Volume
$ 2,127,763
VWAP
2.0746
Average Volume (3m)
1,619,924
Shares Outstanding
122,361,236
Dividend Yield
-
PE Ratio
-1.49
Earnings Per Share (EPS)
-1.4
Revenue
36.86M
Net Profit
-171.67M

About Mersana Therapeutics Inc

Mersana Therapeutics Inc is a clinical stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. Mersana's product candidate, XMT-1536, is... Mersana Therapeutics Inc is a clinical stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. Mersana's product candidate, XMT-1536, is in a Phase 1 clinical trial in patients with tumors expressing NaPi2b, including ovarian cancer, NSCLC, and other cancers. In addition, multiple partners are using Mersana's platform to advance their ADC pipelines. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Wilmington, Delaware, USA
Founded
1970
Mersana Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker MRSN. The last closing price for Mersana Therapeutics was $2.03. Over the last year, Mersana Therapeutics shares have traded in a share price range of $ 0.8014 to $ 6.2801.

Mersana Therapeutics currently has 122,361,236 shares outstanding. The market capitalization of Mersana Therapeutics is $248.39 million. Mersana Therapeutics has a price to earnings ratio (PE ratio) of -1.49.

MRSN Latest News

Mersana Therapeutics to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Β Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.2413.04347826091.842.161.768903511.91262503CS
4-0.1-4.58715596332.182.251.7614043062.04048962CS
12-1.23-37.16012084593.313.631.7616199242.51906735CS
26-1.22-36.96969696973.36.28011.7618946013.64104701CS
52-1.68-44.68085106383.766.28010.801431126422.09347109CS
156-10.86-83.925811437412.9414.80.801420191363.90274315CS
260-1.9-47.73869346733.9829.090.801415387246.62189484CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
VEVVicinity Motor Corporation
$ 0.7131
(122.15%)
116.26M
QLGNQualigen Therapeutics Inc
$ 0.428851
(108.89%)
420.2M
IVPInspire Veterinary Partners Inc
$ 10.52
(88.19%)
41.79M
TOYOTOYO Company Ltd
$ 2.699
(74.13%)
56.65M
NISNNiSun International Enterprise Development Group Company Ltd
$ 9.11
(51.33%)
7.4M
SISIShineco Inc
$ 0.8446
(-60.16%)
6.71M
MCACMonterey Capital Acquisition Corporation
$ 3.54
(-49.50%)
364.7k
MCACUMonterey Capital Acquisition Corporation
$ 7.64
(-28.40%)
2.61k
GENEGenetic Technologies Ltd
$ 0.80
(-27.93%)
780.46k
KZIAKazia Therapeutics Ltd
$ 0.8975
(-27.62%)
25.62M
QLGNQualigen Therapeutics Inc
$ 0.428851
(108.89%)
420.2M
MAXNMaxeon Solar Technologies Ltd
$ 0.237
(-1.54%)
286.13M
NVDANVIDIA Corporation
$ 129.24
(1.44%)
251.65M
AGRIAgriFORCE Growing Systems Ltd
$ 0.1001
(21.92%)
192.82M
LCIDLucid Group Inc
$ 4.25
(25.00%)
167.79M

MRSN Discussion

View Posts
Monksdream Monksdream 1 week ago
MRSN under $2
πŸ‘οΈ0
Victor 11 Victor 11 1 month ago
WLAN will explode within a year
πŸ‘οΈ0
Monksdream Monksdream 2 months ago
MRSN note the cup and handle
πŸ‘οΈ0
TimeFades TimeFades 12 months ago
Looking good still
πŸ‘οΈ0
Triple nickle Triple nickle 12 months ago
Picking up some
πŸ‘οΈ0
TimeFades TimeFades 12 months ago
Time for the push
πŸ‘οΈ0
Penny chatter Penny chatter 12 months ago
Pump it up
πŸ‘οΈ0
TimeFades TimeFades 12 months ago
Pre market pump incoming
πŸ‘οΈ0
Monksdream Monksdream 12 months ago
MRSN new 52 week low
πŸ‘οΈ0
nate2028 nate2028 12 months ago
*some at 0.8
πŸ‘οΈ0
nate2028 nate2028 12 months ago
Grabbed some below 0.8 let’s see
πŸ‘οΈ0
Butchmass Butchmass 1 year ago
Insider buying has happened yesterday. Form 4.
πŸ‘οΈ0
MiamiGent MiamiGent 1 year ago
Nice! Good luck and happy trading!
πŸ‘οΈ0
Butchmass Butchmass 1 year ago
Hey Miami, its already started to bounce.
πŸ‘οΈ0
MiamiGent MiamiGent 1 year ago
MRSN Down 58% on clinical hold. Due to severity of report, not sure of any bounceability.
πŸ‘οΈ0
bladerunner1717 bladerunner1717 1 year ago
MRSN initiated at Citi with a $12 price target.


With Upcoming Ovarian Cancer Data, Analyst Sees 100% Upside For Mersana Therapeutics
Vandana Singh
Fri, January 20, 2023 at 12:16 PM PST
In this article:

MRSN
+9.97%


Citi initiated coverage on Mersana Therapeutics Inc (NASDAQ: MRSN) with a Buy rating and a price target of $12.

The analyst says the topline registrational data (expected in mid-2023) from the UPLIFT Ph2 study evaluating upifitamab rilsodotin (UpRi; NaPi2b ADC) in platinum-resistant ovarian cancer (PROC) will be a catalyst of significant debate.

Citi analyst says that while readout will be binary, investors are underappreciating UPLIFT’s probability of success in NaPi2b-high patients, given the promising efficacy observed in Phase 1.

If the UPLIFT study results are positive, it will lead to a clear pathway to an accelerated approval filing by YE23.

The analyst writes that UpRi’s durability in Phase 1 was in-line or better than single-agent chemo SOC and the recently approved ADC Elahere.

On toxicity, reduced dosing and patient selection strategies should mitigate the risk of Gr4/5 pneumonitis seen earlier in Phase 1.

In December, Mersana announced its third significant collaboration agreement in 2022, reflecting its increasing role as an ADC partner.

The company announced a research collaboration and commercial license agreement with a subsidiary of Merck KGaA (OTC: MKKGY) to discover novel Immunosynthen ADCs directed against up to two targets.

Mersana received an upfront payment of $30 million and is eligible to receive reimbursement of certain costs, up to $800 million in potential milestone payments.

Price Action: MRSN shares are up 10.48% at $6.43 on the last check Friday. (Up more in AH.)

Bladerunner
πŸ‘οΈ0
bladerunner1717 bladerunner1717 1 year ago
MRSN initiated at Citi with a $12 price target.


With Upcoming Ovarian Cancer Data, Analyst Sees 100% Upside For Mersana Therapeutics
Vandana Singh
Fri, January 20, 2023 at 12:16 PM PST
In this article:

MRSN
+9.97%


Citi initiated coverage on Mersana Therapeutics Inc (NASDAQ: MRSN) with a Buy rating and a price target of $12.

The analyst says the topline registrational data (expected in mid-2023) from the UPLIFT Ph2 study evaluating upifitamab rilsodotin (UpRi; NaPi2b ADC) in platinum-resistant ovarian cancer (PROC) will be a catalyst of significant debate.

Citi analyst says that while readout will be binary, investors are underappreciating UPLIFT’s probability of success in NaPi2b-high patients, given the promising efficacy observed in Phase 1.

If the UPLIFT study results are positive, it will lead to a clear pathway to an accelerated approval filing by YE23.

The analyst writes that UpRi’s durability in Phase 1 was in-line or better than single-agent chemo SOC and the recently approved ADC Elahere.

On toxicity, reduced dosing and patient selection strategies should mitigate the risk of Gr4/5 pneumonitis seen earlier in Phase 1.

In December, Mersana announced its third significant collaboration agreement in 2022, reflecting its increasing role as an ADC partner.

The company announced a research collaboration and commercial license agreement with a subsidiary of Merck KGaA (OTC: MKKGY) to discover novel Immunosynthen ADCs directed against up to two targets.

Mersana received an upfront payment of $30 million and is eligible to receive reimbursement of certain costs, up to $800 million in potential milestone payments.

Price Action: MRSN shares are up 10.48% at $6.43 on the last check Friday. (Up more in AH.)

Bladerunner
πŸ‘οΈ0
MRDALE MRDALE 3 years ago
Hey there! I am looking for a stock that will double in a year. Is $MRSN that stock??? Looks like it could. TIA.
MrDale.
πŸ‘οΈ0
daleb2130 daleb2130 3 years ago
Just bought in. $20.27
πŸ‘οΈ0
dealerschool2006 dealerschool2006 4 years ago
Panic sale for MRSN today...results are considered positive...
πŸ‘οΈ0
ClayTrader ClayTrader 4 years ago
* * $MRSN Video Chart 09-14-2020 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
ClayTrader ClayTrader 4 years ago
* * $MRSN Video Chart 05-27-2020 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 4 years ago
MRSN 44%% up,$15.20 going
πŸ‘οΈ0
edwardport edwardport 4 years ago
AWESOME STOCK FOR SURE
πŸ‘οΈ0
edwardport edwardport 4 years ago
fantastic gain today of 21% for all of us expected
πŸ‘οΈ0
TrendTrade2016 TrendTrade2016 4 years ago
MRSN bio beast here...did not take a big hit in the crash!!
πŸ‘οΈ0
TrendTrade2016 TrendTrade2016 4 years ago
MRSN blowing up something is up here!!
πŸ‘οΈ0
BottomBounce BottomBounce 4 years ago
$MRSN GARBAGE Book Value Per Share only $1.73
πŸ‘οΈ0
edwardport edwardport 4 years ago
expect to go higher here
πŸ‘οΈ0
ClayTrader ClayTrader 4 years ago
* * $MRSN Video Chart 04-07-2020 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
sanderburwil sanderburwil 4 years ago
BUYOUT hmmmm
πŸ‘οΈ0
ClayTrader ClayTrader 4 years ago
* * $MRSN Video Chart 01-17-2020 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
ClayTrader ClayTrader 5 years ago
* * $MRSN Video Chart 11-13-19 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
BottomBounce BottomBounce 5 years ago
$MRSN over to BNGO
πŸ‘οΈ0
ClayTrader ClayTrader 5 years ago
* * $MRSN Video Chart 10-10-2019 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
jaybe jaybe 6 years ago
Abstract out for WCLC.....


P2.09-24 - MERS67 is a Novel anti-NaPi2b Antibody and Demonstrates Differential Expression Patterns in Lung Cancer Histologic Subtypes
16:45 - 18:00 | Presenting Author(s): Rebecca Mosher | Author(s): Hui Yu, Kim Ellison, Pamela Shaw, Rafal Dziadziuszko, Eric Hailman, Christopher J. Rivard, Fred R. Hirsch

Abstract
Background
NaPi2b is a sodium-dependent phosphate transporter expressed in lung, ovarian, and thyroid cancers. Prior studies have suggested an enrichment of expression in lung adenocarcinoma (ACA).

XMT-1536 is a NaPi2b targeting ADC (Antibody Drug Conjugate) comprised of a humanized antibody (XMT-1535) conjugated with 10-15 auristatin F-HPA (AF-HPA) payload molecules via the Dolaflexin platform. AF-HPA is capable of controlled bystander-effect killing, resulting in efficacy in models with heterogeneous antigen expression, and is metabolized intra-tumorally to an active non-permeable metabolite to enable greater systemic tolerability. Previously, we demonstrated pre-clinical activity of XMT-1536 in human primary xenograft models of non-small cell lung cancer (NSCLC).

MERS67 is a human-rabbit chimeric antibody derived from XMT-1535. MERS67 has been formatted for use as an immunohistochemical reagent by multiple methods and expression has been shown to correlate with response in an unselected series of primary ovarian cancer xenografts. (AACR-EORTC, 2017)

We evaluated MERS67 to see if it would preferentially stain lung adenocarcinoma (ACA), as has been demonstrated using other NaPi2b antibodies.

Method
An immunohistochemical assay for MERS67 was established on a Leica BondRx Instrument. The assay was performed on tissue microarrays (TMA), including NSCLC and small cell lung cancer (SCLC) cell line arrays, and a NSCLC human tumor array. Tumors in the NSCLC array had previously been classified based on morphologic features only. All arrays were scored based on the H-score method.

To characterize the primary tumors further, the tumor TMA was stained with TTF-1 and p40, markers of ACA and squamous cell carcinoma (SqCC), respectively. Results of this staining were compared to MERS67 staining patterns.

Result
H-Scores in the NSCLC cell line TMA ranged from 0-260, and from 0-100 in the SCLC TMA. Within the tissue microarray, 99 individual cases were evaluable. By morphologic classification 63 cases were SqCC, and 23 cases were ACA. Using an arbitrary cut point of H=50, there was a statistically significant difference in the number of NaPi2b positive ACA cases (19/23) vs SqCC (3/63). Among 43 cases where p40 and TTF-1 were evaluable and were in agreement with morphologic diagnosis, 7/7 cases of ACA were positive for NaPi2b, while 0/36 SqCC were positive.

Conclusion
MERS67 is an anti-NaPi2b antibody that frequently demonstrates immunoreactivity in lung ACA. MERS67 is a chimeric antibody related to XMT-1536, a proprietary anti-NaPi2b ADC. Target expression using MERS67 is being evaluated in an ongoing XMT-1536 Phase 1 clinical trial enrolling non-squamous NSCLC patients.
πŸ‘οΈ0
jaybe jaybe 6 years ago
I would add here if I hadn't loaded up on ADXS last week.

I trust Ana to handle this carefully and professionally and to resolve the hold in less than a month. I assume they are already on dose level 9, since ASCO data cut in May nearly completed DL7 and its a 4-week cycle to assess DLT prior to moving to next dose. Dose level 7 patients have been on drug for three months, with one DLT and one Grade 3 event, AST elevation (reported at ASCO). So far about ~50 patients have been dosed with this payload, including 1522 & 1536, and this is the first Grade 4 or 5 event. All patients are very sick, with average of 4 prior regimens.

Definitely a risk-raising event, but given the established MOA and safety reported to date, I think this will turn out to be a monitorable and manageable event for investigators. Of course this is not good news, but likely outcome will force early reporting of additional safety data around time of Q2 call, pencilled for August 10th.


πŸ‘οΈ0
jaybe jaybe 6 years ago
Mersana...after ASCO...

Looks like a long summer for Mersana. The ASCO data was a real cliff-hanger, responses trending in the right direction, but AEs showing up to, so woefully inconclusive. Doses 8-10 will take ~6-8 weeks each so any meaningful update will be at ENA'18 in mid-November, which is also likely the venue for unveiling the 3rd candidate. Patent app for 3rd drug should publish by end of summer.

In other news, DS-8201 continues to crush the competition and raise the bar for XMT-1522. ASCO data showed 50% ORR for Her-2 low MBC patients. Mersana will need to approach this number with some differentiation in order to compete.

Hopefully XMT-1536 will also reach MTD this year, but readout would be AACR in April at earliest.

πŸ‘οΈ0
jaybe jaybe 6 years ago
New patent app published for new linker/scaffold...

Fairly comprehensive new platform published on WIPO today. Addresses use of new linker/scaffold to achieve higher DAR and greater control of released drug for numerous combinations of antibodies and payloads.

Shows order of magnitude higher potency for conjugates using same XMT-1535 (NaPi2b) against cancer cell lines compared to XMT-1536. Similar results for trastuzumab ADCs in Her2 models.

Looking forward to see how it improves potential of next ADC for colorectal cancer.

https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2018098269&recNum=1&office=&queryString=FP%3A%28mersana%29&prevFilter=&sortOption=Pub+Date+Desc&maxRec=113

πŸ‘οΈ0
dorothy52 dorothy52 6 years ago
It appears that we have the right CEO. Great article, thanks jaybe
πŸ‘οΈ0
jaybe jaybe 6 years ago
Good read on CEO Protopapas's path to Mersana...


page 26...

http://www.qgdigitalpublishing.com/publication/?i=492965&p=4#{%22page%22:26,%22issue_id%22:492965}
πŸ‘οΈ0
jaybe jaybe 6 years ago
Exactly. Looking forward to pre-clinical on next ADC in November at ENA18.

Also should see next-gen platform (payload/linker) presentation at same conference.

Takeda selected ADC will move more slowly, wouldn't be surprised if we don't see data until next year at AACR19.

All eyes on Wednesday 5PM...first clinical data for XMT-1536, sets the table for all science.

DS-8201 showing 60% ORR in Her2+ and 30% ORR in Her-low, those are the benchmarks for a competitive next-gen ADC in MBC.




πŸ‘οΈ0
dorothy52 dorothy52 6 years ago
The prize is in the platform/technology. Stay tune
πŸ‘οΈ0
jaybe jaybe 6 years ago
Another Her2 ADC competitor down for the count....

ADCT-502 was terminated today for safety, joining MEDI4276 as another potent next-gen ADC with potential in Her2-low expressing breast cancer that failed to live up to expectations this year. ADCT-502 was trastuzamab conjugated to a PBD payload at a DAR of 1.7.

DS-8201 remains the only real ADC competitor for XMT-1522 in Her2-low expressing MBC.

https://clinicaltrials.gov/ct2/show/NCT03125200
πŸ‘οΈ0
jaybe jaybe 6 years ago
Mersana ex-CMO lands at Relay Therapeutics....

https://www.firstwordpharma.com/node/1554191?tsid=1
πŸ‘οΈ0
jaybe jaybe 6 years ago
XMT-1522 Late-breaker at AACR in April...

LB-294 / 16 - Synergy of an anti-HER2 ADC TAK-522 (XMT-1522) in combination with anti-PD1 monoclonal antibody (mAb) in a syngeneic breast cancer model expressing human HER2
http://www.abstractsonline.com/pp8/#!/4562/presentation/10611


Also poster on differentiation of ADC platform...
754 / 21 - Unique pharmacologic properties of Dolaflexin-based ADCsβ€”a controlled bystander effect
http://www.abstractsonline.com/pp8/#!/4562/presentation/3082
πŸ‘οΈ0
jaybe jaybe 6 years ago
Potential competitor MEDI4276 flames out...

The wait is over for long overdue clinical data on AZD's "next-gen" Her-2 ADC MEDI4276. Published Phase 1 results this week at TAT demonstrated an ORR of 5% with DLTs and MTD at higher doses. This result most likely signals the end for this candidate as competitors such as DS-8201 already show ORR's over 50% in a similar population (3L), with 31% ORR for Her2-low.

XMT-1522 will need to clear 50% Her2+ and 30% Her2-low hurdles, with differentiating benefits, to be competitive. In the near term only DS-8201, SYD985, and PF-06804103 are "best-in-class" ADC competitors to keep an eye on.

https://academic.oup.com/annonc/article/29/suppl_3/mdy048.005/4917517?searchresult=1
πŸ‘οΈ0
dorothy52 dorothy52 6 years ago
Thanks for the updates jaybe
πŸ‘οΈ0
jaybe jaybe 6 years ago
Article in ADC Review notes Mersana's progress...

Pretty much a recap of JPM updates, potentially five abstracts at AACR in April:

1. Phase 1 data for XMT-1522, safety, efficacy, and RDP2.
2. Pre-clinical on XMT-1536 in IO combo.
3. Pre-clinical on next ADC, IND in 2018.
4. Pre-clinical on Takeda-ADC, IND in mid-2018.
5. Pre-clinical on new platform - new linker and PBD payload.

Likely at least 3 of the above, importantly #1 sets the table for all others. Abstracts posted online March 14.

https://adcreview.com/news/expanding-field-antibody-drug-conjugates/
πŸ‘οΈ0
jaybe jaybe 7 years ago
Notes from JPM: Moving forward on all fronts...

XMT-1522 - 6th dose cohort enrolling, more than needed for efficacy but will dose to MTD. Likely first data at AACR, abstracts publish March 14. Still presenting all 4 cohorts as accelerated opportunities, increased target population for NSCLC to 90K. Takeda to fund 50% of developement post Phase 1.

XMT-1536 - starting 3rd dose cohort - identified addl. indications in basket cohort, enrolling faster than 1522 (likely due to CRO) so will establish MTD by YE.

New platform - new payload, customized linker - likely a PDB per recent patent apps, DAR of 24 is unprecedented, likely presentation at AACR.

XMT-XXXX - New ADC TBA in 2018, colorectal identified in study, likely presentation at AACR.

Takeda ADC - advanced to pre-IND, eligible for milestones in 2018 of $1-2M.

So 4 drugs in clinic by end of 2018.







πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock